Literature DB >> 29905648

Changes in pain intensity after discontinuation of long-term opioid therapy for chronic noncancer pain.

Sterling McPherson1,2,3, Crystal Lederhos Smith1,2, Steven K Dobscha4,5, Benjamin J Morasco4,5, Michael I Demidenko4, Thomas H A Meath4,6, Travis I Lovejoy4,5,7.   

Abstract

Little is known about changes in pain intensity that may occur after discontinuation of long-term opioid therapy (LTOT). The objective of this study was to characterize pain intensity after opioid discontinuation over 12 months. This retrospective U.S. Department of Veterans Affairs (VA) administrative data study identified N = 551 patients nationally who discontinued LTOT. Data over 24 months (12 months before and after discontinuation) were abstracted from VA administrative records. Random-effects regression analyses examined changes in 0 to 10 pain numeric rating scale scores over time, whereas growth mixture models delineated pain trajectory subgroups. Mean estimated pain at the time of opioid discontinuation was 4.9. Changes in pain after discontinuation were characterized by slight but statistically nonsignificant declines in pain intensity over 12 months after discontinuation (B = -0.20, P = 0.14). Follow-up growth mixture models identified 4 pain trajectory classes characterized by the following postdiscontinuation pain levels: no pain (average pain at discontinuation = 0.37), mild clinically significant pain (average pain = 3.90), moderate clinically significant pain (average pain = 6.33), and severe clinically significant pain (average pain = 8.23). Similar to the overall sample, pain trajectories in each of the 4 classes were characterized by slight reductions in pain over time, with patients in the mild and moderate pain trajectory categories experiencing the greatest pain reductions after discontinuation (B = -0.11, P = 0.05 and B = -0.11, P = 0.04, respectively). Pain intensity after discontinuation of LTOT does not, on average, worsen for patients and may slightly improve, particularly for patients with mild-to-moderate pain at the time of discontinuation. Clinicians should consider these findings when discussing risks of opioid therapy and potential benefits of opioid taper with patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29905648      PMCID: PMC6993952          DOI: 10.1097/j.pain.0000000000001315

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  23 in total

1.  Reasons for discontinuation of long-term opioid therapy in patients with and without substance use disorders.

Authors:  Travis I Lovejoy; Benjamin J Morasco; Michael I Demidenko; Thomas H A Meath; Joseph W Frank; Steven K Dobscha
Journal:  Pain       Date:  2017-03       Impact factor: 6.961

2.  Suicidal ideation and suicidal self-directed violence following clinician-initiated prescription opioid discontinuation among long-term opioid users.

Authors:  Michael I Demidenko; Steven K Dobscha; Benjamin J Morasco; Thomas H A Meath; Mark A Ilgen; Travis I Lovejoy
Journal:  Gen Hosp Psychiatry       Date:  2017-04-27       Impact factor: 3.238

3.  Defining trajectories in older adults with back pain presenting in general practice.

Authors:  Wendy T M Enthoven; Bart W Koes; Sita M A Bierma-Zeinstra; Herman J Bueving; Arthur M Bohnen; Wilco C Peul; Maurits W van Tulder; Marjolein Y Berger; Pim A J Luijsterburg
Journal:  Age Ageing       Date:  2016-08-11       Impact factor: 10.668

4.  Identifying Trajectories of Pain Severity in Early Symptomatic Knee Osteoarthritis: A 5-year Followup of the Cohort Hip and Cohort Knee (CHECK) Study.

Authors:  Janet Wesseling; Alex N Bastick; Saskia ten Wolde; Margreet Kloppenburg; Floris P J G Lafeber; Sita M A Bierma-Zeinstra; Johannes W J Bijlsma
Journal:  J Rheumatol       Date:  2015-07-01       Impact factor: 4.666

5.  Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.

Authors:  Erin E Krebs; Amy Gravely; Sean Nugent; Agnes C Jensen; Beth DeRonne; Elizabeth S Goldsmith; Kurt Kroenke; Matthew J Bair; Siamak Noorbaloochi
Journal:  JAMA       Date:  2018-03-06       Impact factor: 56.272

6.  Sustained improvements in pain, mood, function and opioid use post interdisciplinary pain rehabilitation in patients weaned from high and low dose chronic opioid therapy.

Authors:  Kelly L Huffman; Taylor E Rush; Youran Fan; Giries W Sweis; Brinder Vij; Edward C Covington; Judith Scheman; Manu Mathews
Journal:  Pain       Date:  2017-07       Impact factor: 6.961

7.  Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes.

Authors:  B Muthén; L K Muthén
Journal:  Alcohol Clin Exp Res       Date:  2000-06       Impact factor: 3.455

8.  Trajectories and risk profiles of pain in persons with radiographic, symptomatic knee osteoarthritis: data from the osteoarthritis initiative.

Authors:  J E Collins; J N Katz; E E Dervan; E Losina
Journal:  Osteoarthritis Cartilage       Date:  2014-03-21       Impact factor: 6.576

Review 9.  Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy: A Systematic Review.

Authors:  Joseph W Frank; Travis I Lovejoy; William C Becker; Benjamin J Morasco; Christopher J Koenig; Lilian Hoffecker; Hannah R Dischinger; Steven K Dobscha; Erin E Krebs
Journal:  Ann Intern Med       Date:  2017-07-11       Impact factor: 25.391

10.  What have we learned from ten years of trajectory research in low back pain?

Authors:  Alice Kongsted; Peter Kent; Iben Axen; Aron S Downie; Kate M Dunn
Journal:  BMC Musculoskelet Disord       Date:  2016-05-21       Impact factor: 2.362

View more
  9 in total

Review 1.  Complex Persistent Opioid Dependence with Long-term Opioids: a Gray Area That Needs Definition, Better Understanding, Treatment Guidance, and Policy Changes.

Authors:  Ajay Manhapra; Mark D Sullivan; Jane C Ballantyne; R Ross MacLean; William C Becker
Journal:  J Gen Intern Med       Date:  2020-11-06       Impact factor: 5.128

2.  A Cluster-Randomized Clinical Trial to Decrease Prescription Opioid Misuse: Improving the Safety of Opioid Therapy (ISOT).

Authors:  Benjamin J Morasco; Melissa H Adams; Elizabeth R Hooker; Patricia E Maloy; Erin E Krebs; Travis I Lovejoy; Somnath Saha; Steven K Dobscha
Journal:  J Gen Intern Med       Date:  2022-03-16       Impact factor: 5.128

3.  Factors Associated with Pain Treatment Satisfaction Among Patients with Chronic Non-Cancer Pain and Substance Use.

Authors:  Leslie W Suen; Vanessa M McMahan; Christopher Rowe; Sumeet Bhardwaj; Kelly Knight; Margot B Kushel; Glenn-Milo Santos; Phillip Coffin
Journal:  J Am Board Fam Med       Date:  2021 Nov-Dec       Impact factor: 2.395

4.  Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain: a Rapid Review.

Authors:  Katherine Mackey; Johanna Anderson; Donald Bourne; Emilie Chen; Kim Peterson
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

5.  Opioid Discontinuation Among Patients Receiving High-Dose Long-Term Opioid Therapy in the Veterans Health Administration.

Authors:  Taeko Minegishi; Melissa M Garrido; Michael Stein; Elizabeth M Oliva; Austin B Frakt
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

6.  Associations of Pain Numeric Rating Scale Scores Collected during Usual Care with Research Administered Patient Reported Pain Outcomes.

Authors:  Shannon M Nugent; Travis I Lovejoy; Sarah Shull; Steven K Dobscha; Benjamin J Morasco
Journal:  Pain Med       Date:  2021-10-08       Impact factor: 3.750

7.  Clinical and neuroscience evidence supports the critical importance of patient expectations and agency in opioid tapering.

Authors:  Beth D Darnall; Howard L Fields
Journal:  Pain       Date:  2022-05-01       Impact factor: 6.961

8.  Association Between Opioid Dose Reduction Against Patients' Wishes and Change in Pain Severity.

Authors:  Joseph W Frank; Evan Carey; Charlotte Nolan; Anne Hale; Sean Nugent; Erin E Krebs
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

Review 9.  Opioid Receptors in Immune and Glial Cells-Implications for Pain Control.

Authors:  Halina Machelska; Melih Ö Celik
Journal:  Front Immunol       Date:  2020-03-04       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.